-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PNA-5 in Traumatic Brain Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PNA-5 in Traumatic Brain Injury report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PNA-5 in Traumatic Brain Injury Drug Details: PNA-5 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Apabetalone in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apabetalone in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apabetalone in End-Stage Kidney Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pitolisant Hydrochloride in Prader-Willi Syndrome (PWS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pitolisant Hydrochloride in Prader-Willi Syndrome (PWS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pitolisant Hydrochloride in Prader-Willi Syndrome (PWS) Drug Details: Pitolisant...
-
Product Insights
NewSodium And Chloride Dependent Glycine Transporter 1 – Drugs In Development, 2024
The Sodium And Chloride Dependent Glycine Transporter 1 pipeline drugs market research report outlays comprehensive information on the Sodium And Chloride Dependent Glycine Transporter 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Hematological Disorders, Genetic Disorders, and Metabolic Disorders which include indications of Schizophrenia, Cognitive Impairment Associated With Schizophrenia (CIAS), Anemia, Unspecified Hematological...
-
Product Insights
NewAdvanced Glycosylation End Product Specific Receptor – Drugs In Development, 2024
The Advanced Glycosylation End Product Specific Receptor pipeline drugs market research report outlays comprehensive information on the Advanced Glycosylation End Product Specific Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Respiratory, Immunology, and Oncology which include indications of Alzheimer's Disease, Cognitive Disorders, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis, Acute Inflammation, Breast...
-
Product Insights
NewApelin Receptor – Drugs In Development, 2024
The Apelin Receptor pipeline drugs market research report outlays comprehensive information on the Apelin Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Metabolic Disorders, Cardiovascular, Central Nervous System, and Infectious Disease which include indications of Obesity, Type 2 Diabetes, Pulmonary Arterial Hypertension, Unspecified Central Nervous System Disorders, Cognitive Disorders, Coronavirus Disease 2019 (COVID-19), and Coronavirus Disease...
-
Product Insights
NewMas Related G Protein Coupled Receptor MRG – Drugs In Development, 2024
The Mas Related G Protein Coupled Receptor MRG pipeline drugs market research report outlays comprehensive information on the Mas Related G Protein Coupled Receptor MRG targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Infectious Disease, Genetic Disorders, Central Nervous System, and Musculoskeletal Disorders which include indications of Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mazindol CR in Opium (Opioid) Addiction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mazindol CR in Opium (Opioid) Addiction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mazindol CR in Opium (Opioid) Addiction Drug Details: Mazindol...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (CST-2032 + Nadolol) in Dementia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (CST-2032 + Nadolol) in Dementia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (CST-2032 + Nadolol) in Dementia Drug Details: A fixed-dose combination...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OLX-07010 in Progressive Supranuclear Palsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OLX-07010 in Progressive Supranuclear Palsy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OLX-07010 in Progressive Supranuclear Palsy Drug Details: OLX-07010 inhibitor is...